Elicera Therapeutics to Attend Investor and Partnering Events
Elicera Therapeutics announced participation in multiple industry, partnering, and investor events in Q4 2026. The company will present its CARMA study results and iTANK platform.
Uppsala, Sweden – Elicera Therapeutics AB (publ) announced on October 2, 2026, its upcoming participation in several industry, partnering, and investor conferences across Sweden, Europe, and the US during the fourth quarter of 2026. At these events, the company plans to present its business updates, the latest results from the Phase I part of the CARMA clinical study involving its CAR T-cell therapy ELC-301, and its proprietary iTANK platform.
Elicera Therapeutics focuses on developing next-generation immuno-oncology treatments. These treatments are based on iTANK-armed CAR T-cells and oncolytic viruses. The company's CAR T-cell therapy, ELC-301, is currently undergoing clinical development.
The scheduled events offer Elicera Therapeutics a venue to showcase its progress to potential investors and strategic partners within the oncology sector. Presentations will highlight key findings from the Phase I CARMA study, assessing the safety and efficacy of ELC-301.
The company's iTANK platform is designed to enhance the cancer-fighting capabilities of CAR T-cells by enabling them to infiltrate tumors and activate the immune system. This technology is fundamental to Elicera's strategy for creating novel treatments for challenging cancer types.
By engaging in these international conferences, Elicera Therapeutics aims to solidify its role in advancing cancer therapies and facilitate the commercialization of its innovative treatments.